Drug
IL-17i
IL-17i is a pharmaceutical drug with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(100%)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Trials by Status
active_not_recruiting150%
recruiting150%
Recent Activity
2 active trials
Showing 2 of 2
active_not_recruiting
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT05049798
recruiting
A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)
NCT06987292
Clinical Trials (2)
Showing 2 of 2 trials
NCT05049798
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT06987292
A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2